A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations

This publication has 29 references indexed in Scilit:

• Correlates of acute renal failure in patients receiving parenteral amphotericin B
  Kidney International, 2001
• Comparison of Amphotericin B Lipid Complex (ABLC) vs. AmBisome in the Treatment of Suspected or Documented Fungal Infections in Patients with Leukemia
  Leukemia & Lymphoma, 2001
• A Randomized, Double-Blind Comparative Trial Evaluating the Safety of Liposomal Amphotericin B versus Amphotericin B Lipid Complex in the Empirical Treatment of Febrile Neutropenia
  Clinical Infectious Diseases, 2000
• Management of fungal infections in neutropenic patients: more doubts than certainties?
  International Journal of Antimicrobial Agents, 2000
• Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
  New England Journal of Medicine, 1999
• Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study
  Bone Marrow Transplantation, 1999
• Do variations in molecular structure affect the clinical efficacy and safety of lipid-based amphotericin B preparations?
  Leukemia Research, 1997
• Invasive Fungal Infections in Liver Transplant Recipients Receiving Tacrolimus as the Primary Immunosuppressive Agent
  Clinical Infectious Diseases, 1997
• Liposomal amphotericin B (AmBisome) reduces dissemination of infection ad compared with amphotericin B deoxycholate (Fungizone) in a rat model of pulmonary aspergillosis
  Journal of Antimicrobial Chemotherapy, 1996
• LIPOSOMAL AMPHOTERICIN B PREVENTS INVASIVE FUNGAL INFECTIONS IN LIVER TRANSPLANT RECIPIENTS
  Transplantation, 1995